Bioporto: AKI adult study - insights
Yesterday before market closed, Bioporto came out with an announcement about the upcoming USA ICU Adult AKI Clinical Study.
The company appointed Dr. Andrew Allegretti, MD, MSC of Massachusetts General Hospital as the national Principal Investigator (PI) for their upcoming USA clinical study of Acute Kidney Injury (AKI) in adult patients which comprises an initial cut-off and a subsequent validation study. His research has focused on Acute Kidney Injury in the ICU including specialty populations, chronic kidney diseases and cirrhosis/hepatorenal syndrome.
Secondly Bioporto has appointed Propharma as its CRO(Clinical Research Organization) based on their experience with IVDR projects and compatibility with BioPorto’s goals.
Read full announcement here: Bioporto AKI
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 11-10-2024.
Login required
This content is only available for logged in users
BioPorto
BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.
Read more on company page